



Arstat Pharmaceuticals

Transforming Standard of Care for 60+ Million US Women with a De-Risked, Phase III-Ready Pipeline

**Pre-IPO Bridge Financing:
A Rare Near-Term ROI Opportunity**



Contact:

Arkady Rubin, PhD, President/CSO
arubin@arstatinc.com
+1 347-385-0878
www.arstatinfo.com

April 19, 2026

The Arstat Opportunity: Executive Summary

Arstat is taking its Phase III pipeline public in Q1 2027 at a conservative valuation, creating a massive value gap for early investors.

Blue-Chip Leadership: Track Record of Billion-Dollar Successes



Johnson & Johnson



Arkady Rubin, PhD, Founder, President/CSO

- Co-inventor of Ortho Tri-Cyclen Lo® (\$1.8B/year in current market conditions)
- Inventor of all 16 Arstat patents.

Jon Stelzmler, Acting CEO, Prospective Board Member

- Former President of US Lupin
- Former SVP and GM at Bayer (\$1B Women's Health Franchise).

The Pipeline

Four first-in-class products, two are ready for Phase III. Two are likely blockbusters.



Banker Validation

Interest expressed by potential IPO underwriters; two draft engagement letters already received.



Zero debt, clean cap table, and exceptional capital efficiency

A De-Risked, Phase III-Ready Pipeline: Four First-to-Market Products Designed to Dominate Areas of High Unmet Needs

Total Market: > 60 Million US Women

Projected US Sales: \$4.78B (Upside)

A Fortress of 16 Granted US and EU Patents (fully assigned to Arstat prior to the IPO)

| Product | Indication | Status |
|------------------|---|------------------------|
| NUVOCEPT™ | The first oral contraceptive designed for ≈ 20 million women with high BMI Likely Blockbuster | Phase III-ready |
| DUACEPT™ | The first oral contraceptive designed for ≈ 3 million women with cardio risk factors. | Phase III-ready |
| PREMRING™ | A first-in-category vaginal ring for ≈ 14 million women with uterine fibroids and endometriosis Likely Blockbuster | Phase IIb Asset |
| ENHANTA™ | A first-in-category non-hormonal therapy for >25 million women with painful, heavy periods | Phase IIb Asset |

Regulatory Advantage: All products utilize the **505(b)(2) NDA pathway**, leveraging existing data for a much faster, lower-cost route to approval.

For the First Time, Addressing Urging Public Health Priorities

The Problem:

20 million US women with high BMI need reliable birth control, with common choices performing poorly in this group

Our Solution:

NUVOCEPT

(combined oral contraceptive)



Impact: The first-ever, FDA-Validated contraceptive for overweight and obese women, designed as a future standard of care for a growing majority of the market.

The Problem:

13 million US women have had their uterus removed due to uterine fibroids and endometriosis

Our Solution:

PREMRING

(medicated vaginal ring)




Impact: Unrivaled efficacy & safety permit comfortable long-term treatment (unachievable with other therapies), drastically reducing the need for surgeries

“Women will LOVE it.” - Andrea S. Lukes, MD, MHSc, FACOG

(Conducted >150 trials of women’s health products).

The Arbitrage Opportunity: Rewarding Early Investors, Who are Helping to Trigger the IPO

Invest at a **\$10M cap**, target an IPO of **\$120-150M** (pre-money valuation)



Arstat's IPO target is set at a conservative **15-20%** of its \$815M risk-adjusted NPV (rNPV) and current peer valuations, offering **potentially significant post-IPO upside**.

The Ask: Raising a \$1M to Secure a Q1 2027 Nasdaq Listing; Offering 8% of a Future Public Company

The Terms

Raising \$1M via SAFE Note

Valuation Cap: \$10M (Post-Money)

The Opportunity: Secure 8% of a future public company

Use of Funds

The lion's share of capital is dedicated to IPO-readiness activities (see below).

This round will trigger our Q1 2027 IPO with **a projected valuation of \$120–\$150M.**



**60+ Million US Women Have Been Waiting.
So Has a Multi-Billion Dollar Market.**